Gerald Linette

Professor

University of Pennsylvania
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse events of grade 3-4. (7) Cytokine release syndrome and ICANS. (8). Maintenance therapy. Supplemental Figures: (1) Study schematic and subject disposition, (2) Correlates of manufacturing success, (3) Hematopoietic recovery, (4) Post-infusion T cell phenotypes, (5) Correlates of in vivo expansion and manufacturing success, (6) Late post-infusion CAR T cell re-expansion, (7) Soluble BCMA, (8) Late-onset clinical responses, (9) MM cell BCMA expression, (10) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA monotherapy patients, (11) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA + huCART19 combination therapy patients, (12) Sustained post-treatment SOX2-specific T-cell responses.

Year:

2025

We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding to first-line therapy (phase B, N = 20), followed by early lenalidomide or pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance of low-grade neurologic toxicity. Among 15 subjects with measurable disease, 10 exhibited partial response (PR) or better; among 26 subjects responding to prior therapy, 9 improved their response category and 4 converted to minimal residual disease (MRD)–negative complete response/stringent complete response. Early maintenance therapy was safe, feasible, and coincided in some patients with CAR T-cell reexpansion and late-onset, durable clinical response. Outcomes with CART-BCMA + huCART19 were similar to CART-BCMA alone. Collectively, our results demonstrate favorable safety, pharmacokinetics, and antimyeloma activity of dual-target CAR T-cell therapy in early lines of MM treatment. Significance: CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety, pharmacokinetics, and efficacy of CAR T cells in patients with low disease burden, responding to current therapy, combined with standard maintenance therapy. This article is highlighted in the In This Issue feature, p. 101

Year:

2025

A, Expansion of T cells in which stimulation cultures did or did not contain IL7/IL15. B, CD4 and CD8 composition of and C, memory composition of T cell products at the conclusion of manufacturing when stimulation cultures did or did not include IL7/IL15.

Year:

2024

A, Representative ow cytometry plots of transduction efficiency of various synthetic receptors in control (unedited) and TRAC+TRBCKO T cells when editing is performed pre-stimulation. B, Stability of CRISPR editing over-time when performing post-stimulation editing.

Year:

2024

A, Expansion of T cells in which stimulation cultures did or did not contain IL7/IL15. B, CD4 and CD8 composition of and C, memory composition of T cell products at the conclusion of manufacturing when stimulation cultures did or did not include IL7/IL15.

Year:

2024

Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T lymphocytes, leading to the development of practice changing therapies for patients with cancer and the promise of synthetic immune cell therapies for a variety of nonmalignant diseases. Many distinct conceptual and technical approaches have been used to edit T-cell genomes, however targeted assessments of which techniques are most effective for manufacturing, gene editing, and transgene expression are rarely reported. Through extensive comparative evaluation, we identified methods that most effectively enhance engineering of research-scale and preclinical T-cell products at critical stages of manufacturing.

Year:

2024

A, Representative ow cytometry plots of transduction efficiency of various synthetic receptors in control (unedited) and TRAC+TRBCKO T cells when editing is performed pre-stimulation. B, Stability of CRISPR editing over-time when performing post-stimulation editing.

Year:

2024

Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T lymphocytes, leading to the development of practice changing therapies for patients with cancer and the promise of synthetic immune cell therapies for a variety of nonmalignant diseases. Many distinct conceptual and technical approaches have been used to edit T-cell genomes, however targeted assessments of which techniques are most effective for manufacturing, gene editing, and transgene expression are rarely reported. Through extensive comparative evaluation, we identified methods that most effectively enhance engineering of research-scale and preclinical T-cell products at critical stages of manufacturing.

Year:

2024

Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.

Year:

2024

Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T lymphocytes, leading to the development of practice changing therapies for patients with cancer and the promise of synthetic immune cell therapies for a variety of nonmalignant diseases. Many distinct conceptual and technical approaches have been used to edit T-cell genomes, however targeted assessments of which techniques are most effective for manufacturing, gene editing, and transgene expression are rarely reported. Through extensive comparative evaluation, we identified methods that most effectively enhance engineering of research-scale and preclinical T-cell products at critical stages of manufacturing.

Year:

2024

Collaborators (21)

Alfred Garfall

Assistant Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Edward A. Stadtmauer

University of Pennsylvania

UNITED STATES
View details

Stefan Barta

Academic Clinician Associate Professor

University of Pennsylvania

UNITED STATES
View details

Dan Vogl

Associate Professor of Medicine

University of Pennsylvania

UNITED STATES
View details

Saar I. Gill

University of Pennsylvania

UNITED STATES
View details

Elizabeth Hexner

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Daniel J. Powell

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Carl H. June

Professor

University of Pennsylvania

UNITED STATES
View details

Joseph A. Fraietta

University of Pennsylvania

UNITED STATES
View details

Mohamed Abdel-Mohsen

Associate Professor

Northwestern University

UNITED STATES
View details

Nathan Singh

Assistant Professor

Washington University School of Medicine

UNITED STATES
View details

Stefano Pileri

Direttore della Ematopatologia

European Institute of Oncology

ITALY
View details

David Teachey

Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Antonia Rotolo

Imperial College London

UNITED KINGDOM
View details

Adam Snook

Professor

Thomas Jefferson University

UNITED STATES
View details

sandra susanibar adaniya

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Stephen Schuster

Professor, Clinician-Educator

Hospital of the University of Pennsylvania

UNITED STATES
View details

Beatriz M. Carreno

University of Pennsylvania

UNITED STATES
View details

Marco Ruella

PI

University of Pennsylvania

UNITED STATES
View details

Michael Milone

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Adam Cohen

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details